藥明巨諾-B(02126.HK)香港發售股份獲約449.42倍認購 上限定價23.80港元/股
格隆匯 11 月 2日丨藥明巨諾-B(02126.HK)發佈公告，公司擬全球發售9769.2萬股股份，其中香港發售股份4884.6萬股，國際發售股份4884.6萬股，另有15%超額配股權；發售價已釐定為每股發售股份23.80港元，每手買賣單位500股；高盛及UBS為聯席保薦人，預期股份將於2020年11月3日於聯交所主板掛牌上市。
根據香港公開發售初步提呈發售的香港發售股份已獲非常大幅超額認購。合共接獲259,674份有效申請，認購合共約43.91億股，相當於根據香港發售初步可供認購的香港發售股份總數約449.42倍。根據國際發售初步提呈發售的發售股份已獲超額認購，相當於根據國際發售初步可供認購的發售股份總數約28.5倍。
基於發售價每股發售股份23.80港元，根據相關基石投資協議，公司的基石投資者已認購合共4884.25萬股發售股份，合共相當於緊隨全球發售完成後公司已發行股本約12.98%；及全球發售的發售股份數目約50.00%，在兩種情況下均假設超額配股權未獲行使，並無根據股份激勵計劃發行任何額外股份，亦無發行Syracuse保留股份及Juno結算股份。
根據發售價每股23.80港元，公司自全球發售收取的所得款項淨額估計約為21.967億港元(假設超額配股權未獲行使)。公司擬將所得款項淨額約8.787億港元(佔所得款項淨額約40.0%)預期將用於核心候選產品relma-cel；約7.469億港元(佔所得款項淨額的34.0%)預期將用於其他侯選產品；約3.515億港元(佔所得款項淨額的16.0%)預期將用於潛在管線產品；及約2.197億港元(佔所得款項淨額的10.0%)預期將用於營運資金及一般公司用途。 倘超額配股權獲悉數行使，則公司將就因超額配股權獲行使而將予發行及配發的1465.35萬股額外發售股份收取額外所得款項淨額約3.348億港元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
